NL-OMON24039招募中不适用
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)0 个研究点目标入组 222 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Included in EMN02/HO95 trial
- •- The subject must understand and voluntarily sign an informed consent
- •document prior to any study related assessments/procedures.
排除标准
- •- Absolute neutrophil count (ANC) <1.0 x 109/L, unless related to MM.
- •- Platelet count < 75 x 109/L, unless related to MM.
研究者
相似试验
进行中（未招募）
1 期
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) forinduction and consolidation followed by Pomalidomide combined withDexamethason vs Pomalidomide maintenance for patients with MultipleMyeloma in progression after prior 1st line treatment with Lenalidomideand Bortezomib.MedDRA version: 19.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2013-003265-34-CZStichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)222
进行中（未招募）
1 期
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.Multiple MyelomaEUCTR2013-003265-34-ITHOVO222
进行中（未招募）
1 期
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2013-003265-34-ATHOVON Foundation111
进行中（未招募）
1 期
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.Multiple MyelomaEUCTR2013-003265-34-NLHOVON Foundation222
招募中
2 期
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in first relapse after prior 1st line treatment with Lenalidomide and Bortezomib.10018865Multiple MyelomaNL-OMON53109HOVO52